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Abstract
Protocatechuic aldehyde (PCA), a phenolic aldehyde, has therapeutic potency against atherosclerosis. Although PCA is
known to inhibit the migration and proliferation of vascular smooth muscle cells and intravascular thrombosis, the
underlying mechanism remains unclear. In this study, we investigated the protective effect of PCA on endothelial cells and
injured vessels in vivo in association with G protein-coupled estrogen receptor-1 (GPER-1). With PCA treatment, cAMP
production was increased in HUVECs, while GPER-1 expression was increased in both HUVECs and a rat aortic explant. PCA
and G1, a GPER-1 agonist, reduced H2O2 stimulated ROS production in HUVECs, whereas, G15, a GPER-1 antagonist,
increased ROS production further. These elevations were inhibited by co-treatment with PCA or G1. TNFa stimulated the
expression of inflammatory markers (VCAM-1, ICAM-1 and CD40), phospho-NF-kB, phospho-p38 and HIF-1a; however, co-
treatment with PCA or G1 down-regulated this expression significantly. Likewise, increased expression of inflammatory
markers by treatment with G15 was inhibited by co-treatment with PCA. In re-endothelization, aortic ring sprouting and
neointima formation assay, rat aortas treated with PCA or G1 showed accelerated re-endothelization of the endothelium
and reduced sprouting and neointima formation. However, aortas from G15-treated rats showed decelerated re-
endothelization and increased sprouting and neointima formation. The effects of G15 were restored by co-treatment with
PCA or G1. Also, in the endothelia of these aortas, PCA and G1 increased CD31 and GPER-1 and decreased VCAM-1 and
CD40 expression. In contrast, the opposite effect was observed in G15-treated endothelium. These results suggest that
GPER-1 might mediate the protective effect of PCA on the endothelium.
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Introduction
Endothelial dysfunction is an imbalance between vasodilating
and vasoconstricting substances produced by the endothelium
leading to a proinflammatory state and prothrombic properties.
Endothelial dysfunction is an important early event in the
pathogenesis of atherosclerosis. Mechanisms that participate in
endothelial dysfunction include reduced nitric oxide generation,
oxidative excess, and upregulation of adhesion molecules [7,8].
Previous studies on atherosclerosis have provided some informa-
tion on this topic. For example, increased expression of proteins
such as VCAM-1, ICAM-1, E-selectin, CD40, lectin-like oxidized
LDL receptor-1 (LOX-1) [9], production of matrix metallopro-
teinases (MMPs) [10] and reactive oxygen species (ROS), and
decreased secretion levels of NO [11] contribute to both initiation
and progression of atherosclerosis.
Estrogen has protective effects against cardiovascular diseases,
and its receptors ER a and ER b have been shown to mediate
anti-atherogenic effects. Recently, a third membrane-bound ER
has emerged, G protein-coupled estrogen receptor-1 (GPER-1),
that has beneficial effects on the cardiovascular system. GPER-1 is
a seven transmembrane-domain G protein-coupled receptor
(GPCR) that binds to 17b-estradiol (E2) with high affinity and
mediates estrogenic signals [12]. GPER-1 is widely expressed in
human tissues, including the cardiovascular system [13,14]. It was
recently found that selective activation of GPER-1 potently
inhibits the growth of human vascular smooth muscle cells [15].
To find the role of GPER-1 on endothelial protection, G1 (GPER-
1 agonist) and G15 (GPER-1 antagonist) have been evaluated.
These pharmacological agents are currently used most frequently
as tools for investigating the role of GPER-1 in various systems
[12]. In this study, both agents were used to modulate GPER-1 in
vitro and in vivo to investigate the protective role protocatechuic
aldehyde (PCA) has in endothelial dysfunction through GPER-1.
Protocatechuic aldehyde (PCA) is a phenolic aldehyde found in
the aqueous extract of Salvia Miltiorrhiza that has recently been
reported for its anti-oxidative effects. It was recently reported that
PCA reduces myocardial infarct size and the activities of creatine
kinase-MB and cardiac troponin in serum [16]. Also, it can inhibit
migration and proliferation of vascular smooth muscle cells and
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intravascular thrombosis [17]. However, the underlying mecha-
nism of PCA on reducing inflammation and its effects on
endothelial dysfunction remains to be determined. In this study,
we investigated the protective effect of PCA on endothelial cells
and injured vessels in vivo in association with GPER-1.
Materials and Methods
Reagents, Antibodies and assay kits
Protocatechuic aldehyde (PCA) and GPER-1 agonist, G1
(Figure 1 A) were purchased from Sigma Aldrich (St. Louise,
MO, USA). GPER-1 antagonist, G15 was purchased from
Calbiochem (San Diego, CA, USA). TNF-a and rat PDGF-BB
were purchased from R&D Systems (Minneapolis, MN, USA).
Antibodies for western blot analysis against GPER-1 (sc-
134576), VCAM-1 (sc-8304), ICAM-1 (sc-7891), CD31 (sc-
1506), CD40 (sc-975) were purchased from Santa Cruz (Delaware,
CA, USA). phospho-MAPK (#9106S), NFkB (#4767), phospho-
NFkB (#3033S), and HIF-1a (#3716S) were purchased from Cell
Signaling Technology (Danvers, MA, USA).
For ROS activity assay, CM-H2DCFDA kit (#C6827) was
bought from Invitrogen (Carlsbad, CA, USA). For sprout ring
assay, Cultrex BME matrigel (3431-005-01) was bought from
Trevigen (Gaithersburg, MD, USA). MTS assay kit (G3580) was
purchased from Promega (Madison, WI, USA). Cyclic AMP XP
Assay kit (#4339) was brought from Cell signaling (Danvers, MA,
USA)
Ethics Statement
All animal procedures were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) of Yonsei
University Health System (approval number: 2010-0268) and were
performed in strict accordance with the Association for Assessment
and Accreditation of Laboratory Animal Care (AAALAC).
Cell Culture
Primary HUVECs were obtained from GIBCO (C-003-5C).
HUVECs were cultured in EBM-2 (CC-3129) supplemented with
serum kit (CC-4176) purchased from Lonza (Walkersville, MD,
USA). Cells were maintained at 37uC humidified atmosphere of
5% CO2 incubator in collagen-coated dish supplied from Sigma
Aldrich (C9791). The medium was changed every 2 days. For the
experiments, HUVECs passage 3,8 were used after 2 hours of
serum depletion.
Western Blotting
Western blot analysis was performed using antibodies against
GPER-1, VCAM-1, ICAM-1, CD31, CD40, phospho-MAPK,
phospho-NFkB, and HIF-1a. Cells were lysed in buffer containing
10 mM Tris, 400 mM NaCl, 1 mM EDTA, 0.1% NP-40. Protein
concentration of the cell was determined by the Bradford method.
Equal amounts of the whole protein extract were resolved on 10%
SDS gels followed by semi-dry Western blotting. Subsequently,
membranes were blocked with 5% BSA in TBST (50 mM Tris-
HCl, pH 7.5 and 150 mM NaCl containing 0.05% Tween 20).
Blots were probed overnight with the dilutions of antibodies listed
above in 5% BSA containing TBST (10 mM Tris pH 8.0,
150 mM NaCl, 0.05% Tween-20). After incubation with a
secondary anti-rabbit antibody coupled to horseradish peroxidase
immunocomplexes were visualized by enhanced chemi-lumines-
cence.
Animal model – Common Carotid Balloon injury
Male Sprague Dawley rats (SD rats, ORIENT-Charles River
Technology, Seoul, Korea) weighing 200,225 were housed in a
temperature-controlled environment (24,26uC) with a 12/12-
hours reversed light and dark cycle, in a plastic cage with soft
bedding, and given with a free access to tap water and standard
laboratory chow.
7 weeks old rats were randomly divided into seven groups and
they were daily fed with the following amounts: Group 1 –
remained intact; Group 2 – Balloon injury; Group 3 – PCA
(100 mg/kg) with balloon injury; Group 4 – G1 (3.0 mg/kg) with
balloon injury; Group 5 – G15 (3.0 mg/kg) with balloon injury;
Group 6 – G15 (3.0 mg/kg) and PCA (100 mg/kg) with balloon
injury; Group 7 – G15 (3.0 mg/kg) and G1 (3.0 mg/kg) with
balloon injury.
For operative procedures, SD Rats were anesthetized with 5%
isoflurane in a mixture of 70% N2O and 30% O2 and it was
maintained with 2% isoflurane. Also during this procedures, body
temperatures were constantly checked with a rectal probe to
maintain at 37.060.2uC using a homeothermic blanket control
unit and a heating pad (Harvard Appratus, Holliston, MA, USA).
After 2 weeks of intraperitoneal administration, rats’ left common
carotid arteries were isolated and a 2F Forgarty catheter (Edwards
Lifesciences, Irvine, CA, USA) was introduced through the
external carotid arteriotomy incision, advanced to the aortic arch,
inflated to produce moderate resistance, and gradually withdrawn
7 times as previously reported [1].
For Neointimal Formation experiment, animals were injected
with each substance for 4 weeks more after 2 days of recovery and
then sacrificed.
For Re-endothelization assay, animals were injected with each
substance for 1week more after 2 days of recovery and then
injected with Evans Blue through tail vein. They were left injected
for 30 minutes and then sacrificed to obtain the common carotid
artery for evaluation. During these procedures, every effort was
made to minimize animal usage and their suffering.
Measurement of ROS (Reactive Oxygen Species) in
HUVECs
Levels of cellular reactive oxygen species were measured using
the fluorescent probe 5-(and-6)-chloromethyl-29, 79-difluorodihy-
drofluorescein diacetate (CM-H2DFFDA). To prepare for the
ROS assay, HUVECs cultured in EBM-2 supplemented with
serum kit were changed into serum free media with 0.1% serum.
Sample is treated for 24 hours and then, 1 hour of H2O2 100 uM
is added to each dish. After that, ROS assay procedures were
followed as it was described from other studies [2]. Samples were
analyzed with FACS Calibur (BD Biosciences, Franklin Lakes, NJ,
USA).
cAMP activity assay in HUVECs
HUVECs were seeded on 96 well plates in EBM-2 media with
serum kit. After a day of incubation, serum media were replaced
with serum free EBM-2 media with 0.1% FBS serum. After
2 hours of incubation, appropriate substances (Control, PDGF,
PCA, G1, G15, G15+PCA, G15+G1) were added and incubated
for 1 hr. Then steps were followed as it is stated on the
manufacturer’s manual from Cell Signaling (Cell Signaling,
Danvers, MA, USA).
Ex vivo Sprague Dawley Rat’s thoracic aorta culture
Male Sprague Dawley Rats (100 g) were housed in a controlled
environment as previously described. After one week of stabiliza-
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Figure 1. PCA induces expression of GPER-1. (A) The chemical structure of PCA and G1. (B) HUVECs were treated with G1 (3.0 mM) and PCA (10,
50, or 100 mM) for 1 hr to measure the levels of cAMP activity. (C) HUVECs were treated with PCA (100 mM) over 1, 3, 6, 24 hrs. (D) HUVECs were
treated with PCA (10, 50, or 100 mM) for 6 hrs. Blots are representative of 3 independent experiments. Densitometric analyses are presented as the
relative ratio of GPER-1 to b-actin. Data are presented as mean6SEM; * P,0.05. (E) Aortic segments were harvested from Sprague Dawley rats and
cultured ex vivo in serum-free media with PCA (100 mM) over 1, 3, 6, 24 hrs. Segments were than fixed for immunohistochemistry of GPER-1 using 4%
paraformaldehyde.
doi:10.1371/journal.pone.0113242.g001
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tion, under anesthesia, rats were sacrificed and thoracic aortas
were obtained. Thoracic aortas were chopped into several pieces
and placed on Cell Culture Insert (PICM03050) purchased from
Millicell (Billerica, MA, USA) in 6-well plate.
Aortas were maintained in EBM-2 media with serum kit for one
day to make them adapt to the experiment condition. Before the
treatment of PCA, EBM-2 media with serum kit were removed
and replaced with EBM-2 serum free media. After 2 hours of
serum depletion, PCA were added in time dependent manner.
After the treatment, aortas were stored in 4% paraformaldehyde
for fixation in 4uC condition.
Sprout Ring assay
This method was used with some modifications by following
previous work originally reported for mice aorta [3]. Under
anesthesia, thoracic aortas were removed from rat of 100 grams
and transferred to a 50 ml conical tube containing ice-cold serum-
free EBM-2 medium. The peri-aortic fibro-adipose tissue was
carefully removed with fine micro-dissecting forceps not to
damage the aortic wall. Half a millimeter long aortic rings
(approximately 25 per aorta) were sectioned. Ring-shaped explants
of rat aorta were then embedded in BME Matrigel on Coverglass
Bottom dish. EBM-2 serum media was added into the dish and left
to be incubated for 3 days. 3 days later, PCA, G1, G15, G15 and
PCA, and G15 and G1 were added. The cultures were kept at
37uC in a humidified environment for a week and examined every
day with an Olympus microscope at appropriate magnification.
Vascular Histology and Immunohistochemical
procedures
Rat arteries were perfused with saline, removed, and fixed in
4% paraformaldehyde for 24 hours in 4uC. Then, they were
embedded in paraffin and prepared in 4 mm cross sections. Rat
aortas were stained with hematoxylin and eosin using standard
protocol [4,5]. For immunohistochemical analyses, sections were
deparaffinized in xylene, rehydrated in graded ethanol solutions
and washed with distilled water as described from other studies
[6]. Sections were blocked with 5% goat serum (005-000-121,
Jackson ImmunoResearch, West Grove, PA, USA) in antibody
diluent (S2022, Dako, Glostrup, Denmark) for 30 minutes and
incubated overnight at 4uC with following antibodies: GPER-1,
CD40, CD31 and VCAM-1 (1:150). After washing three times in
TBS-T, slides were incubated for 1 hr with a biotinylated
secondary antibody (Vector Laboratories, Burlingame, CA,
USA). After rinsing three times in TBS-T, RTU horseradish
peroxidase streptavidin (SA5704, Vector Laboratories) was applied
and the slides are incubated for 10 minutes. For color develop-
ment, 3,39-diaminobenzidine (DAB, D5637, Sigma) was used.
MTS assay
VSMCs grown on 100 mm are trypsinized and seeded on 96
well plates. After 24 hours of incubation in DMEM serum media,
serum media are replaced with serum free DMEM media. After
24 hours of serum depletion, appropriate drugs (Control, PDGF,
PCA, G1, G15, G15 and PCA, G15 and G1) are added in serum
free DMEM media to each group. For Control and PDGF group
(10 ng/ml), no substances are added. After 24 hours of drug
treatment, media are removed and replaced with PDGF added
drug-containing DMEM media except for Control group. After
24 hours later, steps are followed as it is stated on the
manufacturer’s manual from Promega.
Quantification of in vitro results, sprout length and
neointima size of Rat arteries
To perform image analysis, all images were taken under the
same observation condition (light, contrast, magnification). Image
analysis was performed by using Scion Image software and results
were expressed as mean6SEM. Differences between groups for
both in vivo and vitro results were evaluated using SPSS 18.0
software. Also graphs for Balloon injury, reendothelization assay
and sprout ring assay were done by MedCalc software program.
For morphologic analysis of neointimal formation, six round
cross-sections (4 mm thickness) were cut from the approximate
middle of the artery. The intimal and medial cross-sectional areas
of the carotid arteries were measured, and intima/media ratios
were calculated. Antibody against GPER-1 was used for immu-
nohistochemistry.
Results
PCA increases GPER-1 expression in HUVECs and Sprague
Dawley rat aortas
To assess whether the effect of PCA on human umbilical vein
endothelial cells (HUVECs) is mediated through GPER-1, cAMP
levels and GPER-1 expression were measured after PCA
treatment. PCA increased cAMP levels in a concentration-
dependent manner. Significant elevation of cAMP levels was
observed at 100 mM of PCA. Comparison of elevated cAMP levels
between G1 (3.0 mM) and PCA stimulation showed that PCA was
less potent than G1. GPER-1 expression was increased by PCA
treatment in a concentration dependent manner with the highest
expression after 6 hrs of incubation compared to that of the
control (1.61 fold, P,0.05) (Figure 1C, D). In the ex vivo culture
of rat aortic explants, 100 mM of PCA increased GPER-1
expression after 6 hrs of treatment. (Figure 1E).
PCA decreases ROS production in HUVECs
PCA reduced H2O2 stimulated ROS production in HUVECs in
a concentration-dependent manner. Treatment with 50 or
100 mM of PCA significantly decreased ROS production
(77.3162.56%, P,0.05 and 57.1868.33%, P,0.01) stimulated
by 100 mM H2O2 for 1 hr (Figure 2A). Comparison between G1
(3.0 mM) and PCA (100 mM) showed similar decreases in ROS
production. Whereas, the GPER-1 antagonist G15 (3.0 mM)
increased ROS production further to 132.4765.49% (P,0.05).
This elevation in ROS production was decreased to 78.3367.73%
(P,0.05) and 100.2562.41% (P,0.05) by co-treatment with PCA
or G1, respectively (Figure 2B).
PCA inhibits inflammatory signaling
To evaluate whether PCA could down-regulate the inflamma-
tion in HUVECs caused by TNFa treatment, HUVECs were pre-
treated with PCA (100 mM) or G1 (3.0 mM) for 24 hours [17].
Then, 10 ng/ml TNFa was added for 6 hours to provoke
inflammation. As shown in Figure 3A, TNFa stimulated the
expression of VCAM-1, ICAM-1 and CD40; however, PCA
down-regulated these expression levels significantly. G1 also down-
regulated their expression in a similar manner (Figure 3A).
To investigate inhibition of the NF-kB signaling pathway by
treatment with PCA or G1, endothelial cells were pre-treated with
PCA (100 mM) or G1 (3.0 mM) in the presence or absence of
TNFa (10 ng/ml, 1 hr). As shown in Figure 3B, TNFa increased
the expression of phospho-NF-kB, phospho-p38 and HIF-1a. This
elevated expression was down-regulated significantly by PCA and
G1 (Figure 3B).
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We also investigated whether G15, an antagonist of GPER-1,
affects the expression of inflammatory markers in HUVECs and if
PCA could act as a GPER-1 activator to block the activity of G15.
As shown in Figure 3C, G15 showed GPER-1 inhibition activity
by decreasing the expression level of GPER-1. Also, G15 increased
VCAM-1, ICAM-1 and CD40 compared to the control. However,
PCA treatment increased GPER-1 and inhibited inflammation
markers dramatically.
PCA inhibits angiogenesis
To investigate the effect of PCA on angiogenesis, the Sprout
Ring assay was performed. As shown in Figure 4A, treatment with
PCA (3.7461.89%, P,0.001) or G1 (5.4962.83%, P,0.001)
significantly prevented the length of sprouting compared to the
serum only group (100.0%). Whereas, the addition of G15
(223.9165632.96%, P,0.01) dramatically increased the sprouting
of VSMCs. Co-treatment with PCA or G1 inhibited sprouting
dramatically in Figure S1.
Protocatechuic aldehyde accelerates re-endothelization
in balloon-injured arteries
To investigate whether PCA also protects the endothelium
through GPER-1 under in vivo conditions, endothelial recovery
was evaluated after balloon denudation of the carotid artery in rats
[18].
Sprague Dawley rats were pre-treated with the substances for 2
weeks by intraperitoneal injection and then balloon injury of the
common carotid artery was performed. Rats were injected with
the substances for another 3 days after the surgical procedure.
Before the isolation of carotid arteries, rats were injected with
Evans Blue through the tail vein and left for 30 min. As shown in
Figure 5A, treatment with PCA or G1 accelerated re-endotheliza-
tion in balloon-injured arterial segments. The re-endothelized area
in the PCA- and G1-treated rats was 69.3563.81% (P,0.001)
and 40.2165.21% (P,0.01), respectively, compared to the vehicle
rats. The effect of PCA on re-endothelization was higher
compared to that of G1. G15-treated rats did not show re-
endothelization, similar to the vehicle treatment. Co-treatment of
PCA on G15 treated aortas showed effective re-endothelization
(42.77613.17%, P,0.05), whereas co-treatment of G1 on G15
treated aortas showed partial effects (6.9061.52%, P,0.05)
(Figure 5A).
As shown in Figure 5B, immunostaining for CD31, an
endothelial marker, showed that the PCA- and G1-treated groups
had a clear line of CD31 along the endothelium of the artery.
Whereas, the vehicle- or G15-treated groups showed no staining of
CD31. This suggests that re-endothelization occurred in PCA- or
G1-treated arteries. GPER-1 expression was increased in PCA-
and G1-treated endothelium compared to vehicle-treated arteries.
Treatment with G15 decreased expression of GPER-1. Co-
treatment with G15 and PCA or G1 did not suppress GPER-1
completely, but decreased expression of VCAM-1 and CD40 was
observed. The expression of VCAM-1 and CD40 was increased by
G15 treatment; however, co-treatment with PCA or G1 decreased
their expression (Figure 5B) in the endothelium.
PCA inhibits neointima formation in balloon-injured
common carotid arteries (CCAs)
We investigated the protective effect of PCA and G1 in a
balloon injury model. Sprague Dawley rats (n = 7) were treated for
2 weeks with the substances before the surgical procedure [19].
After balloon injury of the CCA, rats were treated again with the
substances for 4 weeks. After sacrifice, injured CCAs were isolated
and paraffin embedded for H&E staining and immunohistochem-
istry for GPER-1.
Figure 6A shows the representative images of each group
treated with drugs along with bar graphs below. The results clearly
show the effectiveness of PCA and G1 against neointima
formation, whereas G15 increased formation. PCA and G1
attenuated neointimal hyperplasia from 14.0060.95 inches2 to
9.6560.76 inches2 (P,0.001) and 8.41860.73 inches2 (P,0.001),
respectively. However, in G15-treated rats, neointima formation
dramatically accelerated to 17.1661.06 inches2 (P,0.001). The
effect of G15 was inhibited by co-treatment with PCA (6.0660.39
inches2, P,0.001) or G1 (8.4560.58 inches2, P,0.001).
Immunohistochemistry on Figure 6B shows that not only in
early stages of atherosclerosis (Figure 4B) but also after the
formation of neointima, the VCAM-1, CD40, GPER-1 and CD30
follow the similar pattern. This suggest that the treatments of G1
and PCA can effectively down-regulate the inflammatory markers
(VCAM-1 and CD40) and up-regulate GPER-1 and CD31 to
attenuate atherosclerosis for both short and long term. This data
proposes PCA as an effective agent against atherosclerosis.
Discussion
PCA has exhibited various therapeutic effects in different cell
types such as vascular smooth muscle cells, cancer cells, and a
cardiac animal model [17,20,21]. However, PCA has not been
Figure 2. Protocatechuic aldehyde decreases ROS production.
(A) HUVECs were pretreated for 24 hrs with various concentrations (10,
50, 100 mM) of PCA. (B) HUVECs were pretreated for 24 hrs with PCA
(100 mM) and G1 (3.0 mM) and for 6 hrs with G15 (3.0 mM). Then, (A, B)
HUVECs were treated with H2O2 (100 mM/ml) for 1 hr followed by
measurement of ROS levels. (A, B) Both experiments are representative
of 3 independent experiments. Data are presented as mean6SEM; * P,
0.05, ** P,0.005, # indicates P,0.05 compared to the control group.
doi:10.1371/journal.pone.0113242.g002
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evaluated for its effect against endothelial dysfunction and has
rarely been studied in HUVECs. Unlike PCA, GPER-1 has been
consistently reported for its role in attenuating atherosclerosis
because it regulates the activity of many vasoconstrictors and
proliferation of vascular smooth muscle cells [12]. Thus, it is
becoming increasingly difficult to ignore the importance of
endothelial cells and GPER-1 in developing therapeutic agents
against endothelial dysfunction and atherosclerosis.
The activation of GPER-1 by PCA protects endothelial cells in
various ways from inflammation in vitro. One of them is the
inhibition of ROS production, which is closely related to NF-kB.
The reduction of ROS by PCA and GPER-1 agonist has shed
light on the relationship between GPER-1 and NF-kB. Previous
studies have pointed out the beneficial effects of GPER-1 on
atherosclerosis, but they have failed to find connections with NF-
kB [22]. However, we found that G1 and PCA could down-
regulate the secondary molecules involved in NF-kB signaling.
Figure 3. Human umbilical vein endothelial cells (HUVECs) treated with tumor necrosis factor alpha (TNFa) and G15 induces
inflammation. (A, B) HUVECs were pretreated with PCA (100 mM) and G1 (3.0 mM) for 24 hrs. (A) treatment with TNFa (10 ng/ml) for 6 hrs. (B)
treatment with TNFa (10 ng/ml) for 1 hr. (C) HUVECs were pre-treated with PCA (100 mM) for 24 hrs and then treated with G15 (3.0 mM) for 6 hrs.
Blots are representative of 3 independent experiments. (A, B, C) Densitometric analyses are presented as the relative ratio of ICAM-1, VCAM-1, CD40,
HIF-1a, GPER-1 or phospho-p38 to b-actin. (B) Densitometric analyses for phospho-NF-kB are presented as the relative ratio to NF-kB. Data are
presented as mean6SEM; * P,0.05, ** P,0.005, *** P,0.001.
doi:10.1371/journal.pone.0113242.g003
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Such cytokine-mediated upregulation of NF-kB was shown to
implicate HIF-1a [23], CD40 and other adhesion molecules (E-
selectin, VCAM-1 and ICAM-1) [24,25], which were effectively
inhibited by PCA and GPER-1 agonist. We also showed that PCA
and G1 down-regulated the phosphorylation of p38-mitogen
activated protein kinase, which also has been recently reported
from a previous study using ApoE2/2 mice [26]. Although other
possible mechanisms have yet to be ruled out, our results strongly
suggest a model in which PCA increases GPER-1 to down-
regulate inflammatory molecules.
The activation of GPER-1 as a type of GPCR can result in
beneficial effects against inflammation. Cyclic-AMP and Ca2+ are
most frequently associated with GPER-1 signaling. GPER-1
couples to Gas resulting in cAMP production and Gai/o to partly
yield cAMP [12]. PCA and G1 have been shown to increase the
production of cAMP, but it remains unclear whether the GPCR a
subunit of PCA can or cannot be activated. The activation of
GPCR automatically activates regulatory molecules, including
GRKs [27] and b-arrestin [28]. These molecules determine the
role of GPER-1 once they are desensitized. It still remains unclear
whether PCA or G1 can alter the expression of these molecules to
change the fate of GPER-1.
PCA and G1 had inhibitory effects against angiogenesis in the
Sprout Ring assay. In contrast, G15 treatment showed that it
accelerated angiogenesis to a much greater extent than the serum
only group. From the MTS assay (Figure S1), PDGF increased
VSMC proliferation, which was decreased by PCA and G1.
Treatment with G15 increased proliferation, but this angiogenic
effect of G15 was inhibited by co-treatment with PCA or G1.
These results expand the effects of PCA as an anti-angiogenic
agent and show that PCA could interact with proteins other than
Figure 4. Protocatechuic aldehyde exhibits endothelial protection. (A) Re-endothelization of a Sprague Dawley rat carotid artery
determined by Evans Blue staining (de-endothelized areas are stained with blue). Ratios of surface covered by endothelium to the total area in sham,
vehicle, and injured (Inj) groups treated with different substances as follows: PCA, G1, G15, G15+PCA, G15+G1 (n = 4 each). (B) Cross sections of rat
common carotid arteries stained with CD31 antibody 3 days after injury. Also, targets related to inflammatory markers were observed including
VCAM-1, CD40 and GPER-1. Data are presented as mean6SEM; *** indicates P,0.001 compared to the sham group. ## and ### indicate P,0.005
and P,0.001, respectively, compared to the vehicle group. 1 indicates P,0.05 compared to the G15+ Inj. group.
doi:10.1371/journal.pone.0113242.g004
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GPER-1 since most GPCRs and their kinases are known to
accelerate angiogenesis [29].
G15, an antagonist of GPER-1, has been recently discovered
and its effects have not been evaluated in endothelial cells. Its
involvement in blocking estradiol 17b-D-glucuronide-induced
cAMP production [30] and upregulation of the angiotensin AT1
receptor have been reported [31]. Our in vitro results, showed that
G15 acts as a pro-inflammatory agent to increase the expression of
inflammatory markers such as VCAM-1, ICAM-1 and CD40.
Also, the pro-inflammatory characteristics of G15 were observed
for angiogenesis, neointimal formation and attenuation of re-
endothelization. To verify whether PCA can act against the effects
of G15, HUVECs were pre-treated with PCA before treatment
with G15. The results showed that PCA effectively inhibited the
pro-inflammatory effects of G15. Consistent with these results, the
CCA of balloon-injured rats showed that PCA inhibited the pro-
inflammatory effects of G15 by reducing neointimal hyperplasia.
In accordance with the balloon injury results, the endothelia of rat
aortas co-treated with PCA and G15 showed noticeable recovery
from balloon injury.
To reveal the correlation between HUVECs and aortas, we
performed immunohistochemistry for GPER-1, CD40, CD31 and
VCAM-1. We have observed that rats co-treated with PCA and
G1 had definite expression of CD31 and GPER-1, suggesting that
GPER-1 affects endothelial cell survival. Also, the immunohisto-
chemistry results for CD40 and VCAM-1 showed that PCA and
G1 effectively inhibited both these molecules, similar to observa-
tions from the HUVEC experiment. In contrast, aortas from G15-
treated rats did not show expression of either GPER-1 or CD31.
Surprisingly, immunohistochemistry for VCAM-1 and CD40 was
clearly observed in the vehicle and G15-treated groups. Further-
more, co-treatment with G15 and PCA or G1 in rats showed
recovery of CD31 and GPER-1, indicating that PCA and G1 act
through GPER-1 in a similar manner.
To further explain the various roles of PCA in the endothelium,
studies on the structure of PCA are required. O9Brien et al [32]
Figure 5. PCA inhibits angiogenesis. (A) Rat aortas were obtained from Sprague Dawley rats weighing 100 grams. Rat aorta segments placed on
Matrigel were stimulated with FBS (10%) for 3 days. Then, the segments were treated with each substance for 48 hrs in media supplemented with
FBS (10%). Sprout lengths were measured by using Scion Image software. (A, B) Values represent the means 6 SEMs of 3 experiments. *** indicates
P,0.001 compared to the control group.## and### indicate P,0.005 and P,0.001, respectively, compared to the PDGF group. 111 indicates P,
0.001 compared to the G15 group. Production will need this reference to link the reader to the figure.
doi:10.1371/journal.pone.0113242.g005
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showed that aldehyde has therapeutic effects against some human
diseases. Therefore, we have previously compared two different
protocatechuic substances, aldehyde and its acid form, in order to
reveal the structural function of this particular molecule. We
showed that protocatechuic acid does not have the same
therapeutic effects as the aldehyde form. This provided us with
information on the structural importance of this molecule with
respect to endothelial dysfunction. Further research will be
required to elucidate the structural function of PCA for the
development of new drugs against atherosclerosis.
GPER-1 and ring-structured aldehyde may be closely associated
with each other. A recent study by Hamza et al [33] showed that
hydroxyproline, which is one of the ring-structured aldehydes,
activates GPER-1 through a different mechanism from estrogen.
They also suggested that it stabilizes the active site of GPER-1 by
forming a network of hydrogen bonds between the residues of
GPER-1. PCA and 3,4-dihydroxybenzaldehyde share many
structural features with hydroxyproline that need to be evaluated
to confirm whether PCA acts in a similar manner as hydroxypro-
line. However, in the present study, we compared data on PCA
and G1 and showed that PCA exhibited similar therapeutic effects
as G1, thus demonstrating the likelihood that PCA can act like
hydroxyproline.
Currently, it is difficult task to find the exact mode of activation
by PCA. So, by comparing the effects of G1 and PCA in the
presence of G15, it would clarify the function of PCA whether it
can act like G1 or GPER-1 agonist in activating cAMP. The
results from Figure S2A show that the treatment of PCA or G1 in
Figure 6. The effects of PCA, G1, G15, G15+PCA, and G15+G1 in CCA balloon-injured Sprague Dawley rats. (A, B) Seven-week-old
Sprague Dawley rats (200 g) were treated with each substance by intraperitoneal injection for 2 weeks and then common carotid arteries from the
rats were balloon injured. Substances were injected for another 4 weeks and then sacrificed for (A) H & E staining of common carotid arteries. Graph
shows the percentage of neointima areas of Sprague Dawley rats from each group (n = 7). Measurements were made using Scion Image software. (B)
immunohistochemistry of rat aortas shows GPER-1 expression in the linings of the aorta from the same tissues used for Figure 5A. Data are presented
as mean6SEM; *** indicates P,0.001 compared to the sham group. ### indicates P,0.001 compared to the vehicle group. 111 indicates P,0.001
compared to the G15 + Inj. group.
doi:10.1371/journal.pone.0113242.g006
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the presence of G15 decreased cAMP in similar degree in
comparison to the HUVECs treated with PCA or G1 without
G15. This shows that PCA and G1 share the similar mechanism in
interacting with GPER-1 for cAMP activation and that their
activity cannot be fully inhibited by the treatment G15. This
implicates that PCA can interact with GPER-1 like G1 agonist.
Further researches are needed to find whether PCA and GPER-1
bind directly or not. To further verify the relationship between
PCA and GPER-1 and G15’s intervention in this relationship, we
have treated G15 to HUVECs to see whether G15 can inhibit the
cAMP activity of GPER-1. In Figure S2A shows that G15 has a
mild inhibitory effect on cAMP activity. Also, the co-treatment of
G15 with PCA or G1 has decreased activity level compared to
PCA or G1 only treated group. This shows that G15, which is
unknown for its capability on GPER-1 mechanism, does a slight
inhibition on cAMP activity of GPER-1 in HUVECs. Also similar
patterns were observed in Figure S2B as it mildly inhibits p-
AMPK, which is well-known downstream protein of cAMP,
increased by PCA and G1. This data suggests G15’s inhibitory
effect depend less on cAMP inhibition to cause inflammatory and
oxidative effects. We believe that there are non-cAMP pathways
that G15 can act on during GPER-1 activation. Further researches
are needed to verify the G15’s action on GPER-1 as an antagonist
of GPER-1.
In summary, the present study provides the first evidence that
PCA attenuates endothelial dysfunction and atherosclerosis in
vitro and in vivo through activation of GPER-1. These findings
indicate that PCA is an important candidate compound for the
treatment of atherosclerosis.
Supporting Information
Figure S1 PCA’s inhibition on VSMC cell proliferation.
Media of VSMCs in 96 well were changed to serum free media for
24 hrs. Then, PCA (100 mM), G1 (3.0 mM) and G15 (3.0 mM)
were treated for 24 hrs. After that, PDGF (10 ng/ml) was treated
for 24 hrs. Graphs are representative of 3 independent experi-
ments. *** indicates P,0.001 compared to the sham group. ##,
### indicates P,0.005, P,0.001, respectively to PDGF group.
$$$ indicates P,0.0001 compared to PDGF+G15 group.
Production will need this reference to link the reader to the figure.
(TIF)
Figure S2 PCA and G15 effects on GPER-1 related
mechanism. (A) HUVECs in 96 well were treated with adequate
substances (PCA, G1, G15, G15+PCA, G15+G1) for 1 hr after
2 hrs of serum depletion. Graphs are representative of 3
independent experiments. * indicates P,0.05 compared to the
control and G15 treated group. (B) HUVECs were pretreated with
adequate substances for 24 hrs (PCA, 100 mM; G1, 3.0 mM). Then
G15 (3.0 mM) were added for 6 hrs for p-AMPK and AMPK.
Blots are representative of 3 independent experiments. * indicates
P,0.05 compared to the control group. # indicates P,0.05
compared to the G15 group.
(TIF)
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